Thomas Morris Appointed as Medical Director
PHILADELPHIA (August 18, 2016) – InClinica, a global, clinical CRO, announced that Dr. Thomas Morris, has been appointed Medical Director of InClinica Ltd., representing the company’s European operations. Based in the U.K., Dr. Morris will contribute his extensive expertise in the design and execution of InClinica clients’ clinical development plans as well as his deep knowledge of EU regulatory practices.
Dr. Morris has more than 20 years of experience through all phases of global drug development, particularly in the development of cancer therapies and related regimens. He has represented companies in interactions with global thought leaders and regulatory agencies in the U.S., Europe, and key Asian territories. Most recently, he served as Senior Medical Director of Oncology at AstraZeneca.
“Tom brings a wealth of knowledge and experience to InClinica’s European operations,” said John Pearson, InClinica’s General Manager, Europe. “Our presence continues to expand in Europe, and his rich history in product strategy, life cycle management, and refining development pathways strengthens our services overseas.”
Dr. Morris holds Science and Medical degrees from the University of Wales, is a member of the Royal College of Physicians, holds a Diploma in Pharmaceutical Medicine, is a Fellow of the Faculty of Pharmaceutical Medicine and a sits on its board of Trustees. He also holds a Master of Laws degree.
# # #
About InClinica
InClinica is a global clinical contract research organization founded in 2016 after the acquisition of an existing global CRO. With a senior management team that brings more than 100 combined years of experience, InClinica works across all phases of the clinical research process and has a particular strength in first in man and phase 2 studies. InClinica is headquartered in Philadelphia with other locations in the U.K., Israel, and Malaysia/Singapore.
